Tropomyosin receptor kinase C (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tropomyosin receptor kinase C" in English language version.

refsWebsite

Global rank English rank

52nih.gov

4^th place

36doi.org

2^nd place

10semanticscholar.org

11^th place

8^th place

3harvard.edu

18^th place

17^th place

2ensembl.org

1,626^th place

1,007^th place

1reactome.org

low place

1sciencedirect.com

149^th place

178^th place

doi.org

McGregor LM, Baylin SB, Griffin CA, Hawkins AL, Nelkin BD (July 1994). "Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal assignment, and evidence for a splice variant". Genomics. 22 (2): 267–72. doi:10.1006/geno.1994.1383. PMID 7806211.
Tsoulfas, P. (2018). "Signaling by NTRK3 (TRKC)". Reactome - A Curated Knowledgebase of Biological Pathways. 65. doi:10.3180/R-HSA-9034015.1. S2CID 89660152.
Takahashi H, Arstikaitis P, Prasad T, Bartlett TE, Wang YT, Murphy TH, Craig AM (January 2011). "Postsynaptic TrkC and presynaptic PTPσ function as a bidirectional excitatory synaptic organizing complex". Neuron. 69 (2): 287–303. doi:10.1016/j.neuron.2010.12.024. PMC 3056349. PMID 21262467.
Tsoulfas P, Stephens RM, Kaplan DR, Parada LF (March 1996). "TrkC isoforms with inserts in the kinase domain show impaired signaling responses". The Journal of Biological Chemistry. 271 (10): 5691–7. doi:10.1074/jbc.271.10.5691. PMID 8621434.
Naito Y, Lee AK, Takahashi H (March 2017). "Emerging roles of the neurotrophin receptor TrkC in synapse organization". Neuroscience Research. 116 (2017): 10–17. doi:10.1016/j.neures.2016.09.009. PMID 27697534. S2CID 44805812.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. (February 2018). "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children". The New England Journal of Medicine. 378 (8): 731–739. doi:10.1056/NEJMoa1714448. PMC 5857389. PMID 29466156.
Benito-Gutiérrez E, Garcia-Fernàndez J, Comella JX (February 2006). "Origin and evolution of the Trk family of neurotrophic receptors". Molecular and Cellular Neurosciences. 31 (2): 179–92. doi:10.1016/j.mcn.2005.09.007. PMID 16253518. S2CID 25232377.
Bouzas-Rodriguez J, Cabrera JR, Delloye-Bourgeois C, Ichim G, Delcros JG, Raquin MA, et al. (March 2010). "Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis". The Journal of Clinical Investigation. 120 (3): 850–8. doi:10.1172/jci41013. PMC 2827960. PMID 20160348.
Barbacid M (April 1995). "Neurotrophic factors and their receptors". Current Opinion in Cell Biology. 7 (2): 148–55. doi:10.1016/0955-0674(95)80022-0. PMID 7612265. S2CID 12525700.
Jin W (January 2020). "Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer". Cancers. 12 (1): 147. doi:10.3390/cancers12010147. PMC 7016819. PMID 31936239..
Saragovi HU, Galan A, Levin LA (31 January 2019). "Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration". Frontiers in Cellular Neuroscience. 13 (231): 231. doi:10.3389/fncel.2019.00231. PMC 6563757. PMID 31244606.
Kue CS, Kamkaew A, Voon SH, Kiew LV, Chung LY, Burgess K, Lee HB (November 2016). "Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy". Scientific Reports. 6 (37209): 37209. Bibcode:2016NatSR...637209K. doi:10.1038/srep37209. PMC 5112560. PMID 27853305.
Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M (December 1982). "Oncogenes in solid human tumours". Nature. 300 (5892): 539–42. Bibcode:1982Natur.300..539P. doi:10.1038/300539a0. PMID 7144906. S2CID 30179526.
Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, et al. (October 2015). "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101". Cancer Discovery. 5 (10): 1049–57. doi:10.1158/2159-8290.CD-15-0443. PMC 4635026. PMID 26216294.
Jin W, Kim GM, Kim MS, Lim MH, Yun C, Jeong J, et al. (November 2010). "TrkC plays an essential role in breast tumor growth and metastasis". Carcinogenesis. 31 (11): 1939–47. doi:10.1093/carcin/bgq180. PMID 20802235.
Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, et al. (May 2009). "Trk receptor expression and inhibition in neuroblastomas". Clinical Cancer Research. 15 (10): 3244–50. doi:10.1158/1078-0432.ccr-08-1815. PMC 4238907. PMID 19417027.
Huong LD, Shin JA, Choi ES, Cho NP, Kim HM, Leem DH, Cho SD (July 2012). "β-Phenethyl isothiocyanate induces death receptor 5 to induce apoptosis in human oral cancer cells via p38". Oral Diseases. 18 (5): 513–9. doi:10.1111/j.1601-0825.2012.01905.x. PMID 22309674.
Grotzer MA, Janss AJ, Fung K, Biegel JA, Sutton LN, Rorke LB, et al. (March 2000). "TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors". Journal of Clinical Oncology. 18 (5): 1027–35. doi:10.1200/jco.2000.18.5.1027. PMID 10694553.
Luo Y, Kaz AM, Kanngurn S, Welsch P, Morris SM, Wang J, et al. (2013-07-11). "NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer". PLOS Genetics. 9 (7): e1003552. doi:10.1371/journal.pgen.1003552. PMC 3708790. PMID 23874207.
Behrouz Sharif S, Hashemzadeh S, Mousavi Ardehaie R, Eftekharsadat A, Ghojazadeh M, Mehrtash AH, et al. (December 2016). "Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker". Oncology Letters. 12 (6): 5335–5343. doi:10.3892/ol.2016.5327. PMC 5228494. PMID 28105243.
Kuo IY, Chang JM, Jiang SS, Chen CH, Chang IS, Sheu BS, et al. (2014). "Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients". International Journal of Medical Sciences. 11 (8): 779–87. doi:10.7150/ijms.7405. PMC 4057483. PMID 24936140.
Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, et al. (November 2020). "Evaluating entrectinib as a treatment option for non-small cell lung cancer". Expert Opinion on Pharmacotherapy. 21 (16): 1935–1942. doi:10.1080/14656566.2020.1798932. PMID 32736487. S2CID 220907958.
Marcus L, Donoghue M, Aungst S, Myers CE, Helms WS, Shen G, et al. (February 2021). "FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors". Clinical Cancer Research. 27 (4): 928–932. doi:10.1158/1078-0432.CCR-20-2771. PMID 32967940. S2CID 221886243.
Coles CH, Mitakidis N, Zhang P, Elegheert J, Lu W, Stoker AW, et al. (November 2014). "Structural basis for extracellular cis and trans RPTPσ signal competition in synaptogenesis". Nature Communications. 5 (5209): 5209. Bibcode:2014NatCo...5.5209C. doi:10.1038/ncomms6209. PMC 4239663. PMID 25385546.
Lamballe, L; Klein, R; Barbecid, M (6 September 1991). "TrkC, a new member of the TrkC family of tyrosine protein kinases, is a receptor for Neurotrophin-3". Cell. 66 (5): 967–979. doi:10.1016/0092-8674(91)90442-2. PMID 1653651. S2CID 23448391.
Philo, J; Talvenheimo, J; Wen, J; Rosenfeld, R; Welcher, A; Arakawa, T (11 November 1994). "Interactions of Neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), and the NT-3. BDNF heterodimer with the extracellular domains of the TrkB and TrkC receptors". Journal of Biological Chemistry. 269 (45): 27840–27846. doi:10.1016/S0021-9258(18)46863-9. PMID 7961713.
Tsoulfas P, Stephens RM, Kaplan DR, Parada LF (March 1996). "TrkC isoforms with inserts in the kinase domain show impaired signaling responses". The Journal of Biological Chemistry. 271 (10): 5691–7. doi:10.1074/jbc.271.10.5691. PMID 8621434.
Huang EJ, Reichardt LF (March 2001). "Neurotrophins: roles in neuronal development and function". Annual Review of Neuroscience. 24: 677–736. doi:10.1146/annurev.neuro.24.1.677. PMC 2758233. PMID 11520916.
Werner P, Paluru P, Simpson AM, Latney B, Iyer R, Brodeur GM, Goldmuntz E (December 2014). "Mutations in NTRK3 suggest a novel signaling pathway in human congenital heart disease". Human Mutation. 35 (12): 1459–68. doi:10.1002/humu.22688. PMC 4247247. PMID 25196463.
Jin W, Yun C, Kwak MK, Kim TA, Kim SJ (December 2007). "TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling". Oncogene. 26 (55): 7684–91. doi:10.1038/sj.onc.1210571. PMID 17546043. S2CID 44016529.
Shi L, Yue J, You Y, Yin B, Gong Y, Xu C, et al. (November 2006). "Dok5 is substrate of TrkB and TrkC receptors and involved in neurotrophin induced MAPK activation". Cellular Signalling. 18 (11): 1995–2003. doi:10.1016/j.cellsig.2006.03.007. PMID 16647839.
Jin W, Yun C, Kim HS, Kim SJ (October 2007). "TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling". Cancer Research. 67 (20): 9869–77. doi:10.1158/0008-5472.CAN-07-0436. PMID 17942918.
Marsh HN, Palfrey HC (September 1996). "Neurotrophin-3 and brain-derived neurotrophic factor activate multiple signal transduction events but are not survival factors for hippocampal pyramidal neurons". Journal of Neurochemistry. 67 (3): 952–63. doi:10.1046/j.1471-4159.1996.67030952.x. PMID 8752100.
Yuen EC, Mobley WC (September 1999). "Early BDNF, NT-3, and NT-4 signaling events". Experimental Neurology. 159 (1): 297–308. doi:10.1006/exnr.1999.7148. PMID 10486198. S2CID 31007329.
Zaccaro MC, Lee HB, Pattarawarapan M, Xia Z, Caron A, L'Heureux PJ, et al. (September 2005). "Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities". Chemistry & Biology. 12 (9): 1015–28. doi:10.1016/j.chembiol.2005.06.015. PMID 16183026.
Brahimi F, Malakhov A, Lee HB, Pattarawarapan M, Ivanisevic L, Burgess K, Saragovi HU (October 2009). "A peptidomimetic of NT-3 acts as a TrkC antagonist". Peptides. 30 (10): 1833–9. doi:10.1016/j.peptides.2009.07.015. PMC 2755609. PMID 19647025.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000140538 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000059146 – Ensembl, May 2017

harvard.edu

ui.adsabs.harvard.edu

Kue CS, Kamkaew A, Voon SH, Kiew LV, Chung LY, Burgess K, Lee HB (November 2016). "Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy". Scientific Reports. 6 (37209): 37209. Bibcode:2016NatSR...637209K. doi:10.1038/srep37209. PMC 5112560. PMID 27853305.
Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M (December 1982). "Oncogenes in solid human tumours". Nature. 300 (5892): 539–42. Bibcode:1982Natur.300..539P. doi:10.1038/300539a0. PMID 7144906. S2CID 30179526.
Coles CH, Mitakidis N, Zhang P, Elegheert J, Lu W, Stoker AW, et al. (November 2014). "Structural basis for extracellular cis and trans RPTPσ signal competition in synaptogenesis". Nature Communications. 5 (5209): 5209. Bibcode:2014NatCo...5.5209C. doi:10.1038/ncomms6209. PMC 4239663. PMID 25385546.

nih.gov

pubmed.ncbi.nlm.nih.gov

McGregor LM, Baylin SB, Griffin CA, Hawkins AL, Nelkin BD (July 1994). "Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal assignment, and evidence for a splice variant". Genomics. 22 (2): 267–72. doi:10.1006/geno.1994.1383. PMID 7806211.
Takahashi H, Arstikaitis P, Prasad T, Bartlett TE, Wang YT, Murphy TH, Craig AM (January 2011). "Postsynaptic TrkC and presynaptic PTPσ function as a bidirectional excitatory synaptic organizing complex". Neuron. 69 (2): 287–303. doi:10.1016/j.neuron.2010.12.024. PMC 3056349. PMID 21262467.
Tsoulfas P, Stephens RM, Kaplan DR, Parada LF (March 1996). "TrkC isoforms with inserts in the kinase domain show impaired signaling responses". The Journal of Biological Chemistry. 271 (10): 5691–7. doi:10.1074/jbc.271.10.5691. PMID 8621434.
Naito Y, Lee AK, Takahashi H (March 2017). "Emerging roles of the neurotrophin receptor TrkC in synapse organization". Neuroscience Research. 116 (2017): 10–17. doi:10.1016/j.neures.2016.09.009. PMID 27697534. S2CID 44805812.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. (February 2018). "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children". The New England Journal of Medicine. 378 (8): 731–739. doi:10.1056/NEJMoa1714448. PMC 5857389. PMID 29466156.
Benito-Gutiérrez E, Garcia-Fernàndez J, Comella JX (February 2006). "Origin and evolution of the Trk family of neurotrophic receptors". Molecular and Cellular Neurosciences. 31 (2): 179–92. doi:10.1016/j.mcn.2005.09.007. PMID 16253518. S2CID 25232377.
Bouzas-Rodriguez J, Cabrera JR, Delloye-Bourgeois C, Ichim G, Delcros JG, Raquin MA, et al. (March 2010). "Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis". The Journal of Clinical Investigation. 120 (3): 850–8. doi:10.1172/jci41013. PMC 2827960. PMID 20160348.
Barbacid M (April 1995). "Neurotrophic factors and their receptors". Current Opinion in Cell Biology. 7 (2): 148–55. doi:10.1016/0955-0674(95)80022-0. PMID 7612265. S2CID 12525700.
Jin W (January 2020). "Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer". Cancers. 12 (1): 147. doi:10.3390/cancers12010147. PMC 7016819. PMID 31936239..
Saragovi HU, Galan A, Levin LA (31 January 2019). "Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration". Frontiers in Cellular Neuroscience. 13 (231): 231. doi:10.3389/fncel.2019.00231. PMC 6563757. PMID 31244606.
Kue CS, Kamkaew A, Voon SH, Kiew LV, Chung LY, Burgess K, Lee HB (November 2016). "Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy". Scientific Reports. 6 (37209): 37209. Bibcode:2016NatSR...637209K. doi:10.1038/srep37209. PMC 5112560. PMID 27853305.
Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M (December 1982). "Oncogenes in solid human tumours". Nature. 300 (5892): 539–42. Bibcode:1982Natur.300..539P. doi:10.1038/300539a0. PMID 7144906. S2CID 30179526.
Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, et al. (October 2015). "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101". Cancer Discovery. 5 (10): 1049–57. doi:10.1158/2159-8290.CD-15-0443. PMC 4635026. PMID 26216294.
Jin W, Kim GM, Kim MS, Lim MH, Yun C, Jeong J, et al. (November 2010). "TrkC plays an essential role in breast tumor growth and metastasis". Carcinogenesis. 31 (11): 1939–47. doi:10.1093/carcin/bgq180. PMID 20802235.
Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, et al. (May 2009). "Trk receptor expression and inhibition in neuroblastomas". Clinical Cancer Research. 15 (10): 3244–50. doi:10.1158/1078-0432.ccr-08-1815. PMC 4238907. PMID 19417027.
Huong LD, Shin JA, Choi ES, Cho NP, Kim HM, Leem DH, Cho SD (July 2012). "β-Phenethyl isothiocyanate induces death receptor 5 to induce apoptosis in human oral cancer cells via p38". Oral Diseases. 18 (5): 513–9. doi:10.1111/j.1601-0825.2012.01905.x. PMID 22309674.
Grotzer MA, Janss AJ, Fung K, Biegel JA, Sutton LN, Rorke LB, et al. (March 2000). "TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors". Journal of Clinical Oncology. 18 (5): 1027–35. doi:10.1200/jco.2000.18.5.1027. PMID 10694553.
Luo Y, Kaz AM, Kanngurn S, Welsch P, Morris SM, Wang J, et al. (2013-07-11). "NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer". PLOS Genetics. 9 (7): e1003552. doi:10.1371/journal.pgen.1003552. PMC 3708790. PMID 23874207.
Behrouz Sharif S, Hashemzadeh S, Mousavi Ardehaie R, Eftekharsadat A, Ghojazadeh M, Mehrtash AH, et al. (December 2016). "Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker". Oncology Letters. 12 (6): 5335–5343. doi:10.3892/ol.2016.5327. PMC 5228494. PMID 28105243.
Kuo IY, Chang JM, Jiang SS, Chen CH, Chang IS, Sheu BS, et al. (2014). "Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients". International Journal of Medical Sciences. 11 (8): 779–87. doi:10.7150/ijms.7405. PMC 4057483. PMID 24936140.
Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, et al. (November 2020). "Evaluating entrectinib as a treatment option for non-small cell lung cancer". Expert Opinion on Pharmacotherapy. 21 (16): 1935–1942. doi:10.1080/14656566.2020.1798932. PMID 32736487. S2CID 220907958.
Marcus L, Donoghue M, Aungst S, Myers CE, Helms WS, Shen G, et al. (February 2021). "FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors". Clinical Cancer Research. 27 (4): 928–932. doi:10.1158/1078-0432.CCR-20-2771. PMID 32967940. S2CID 221886243.
Coles CH, Mitakidis N, Zhang P, Elegheert J, Lu W, Stoker AW, et al. (November 2014). "Structural basis for extracellular cis and trans RPTPσ signal competition in synaptogenesis". Nature Communications. 5 (5209): 5209. Bibcode:2014NatCo...5.5209C. doi:10.1038/ncomms6209. PMC 4239663. PMID 25385546.
Lamballe, L; Klein, R; Barbecid, M (6 September 1991). "TrkC, a new member of the TrkC family of tyrosine protein kinases, is a receptor for Neurotrophin-3". Cell. 66 (5): 967–979. doi:10.1016/0092-8674(91)90442-2. PMID 1653651. S2CID 23448391.
Philo, J; Talvenheimo, J; Wen, J; Rosenfeld, R; Welcher, A; Arakawa, T (11 November 1994). "Interactions of Neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), and the NT-3. BDNF heterodimer with the extracellular domains of the TrkB and TrkC receptors". Journal of Biological Chemistry. 269 (45): 27840–27846. doi:10.1016/S0021-9258(18)46863-9. PMID 7961713.
Tsoulfas P, Stephens RM, Kaplan DR, Parada LF (March 1996). "TrkC isoforms with inserts in the kinase domain show impaired signaling responses". The Journal of Biological Chemistry. 271 (10): 5691–7. doi:10.1074/jbc.271.10.5691. PMID 8621434.
Huang EJ, Reichardt LF (March 2001). "Neurotrophins: roles in neuronal development and function". Annual Review of Neuroscience. 24: 677–736. doi:10.1146/annurev.neuro.24.1.677. PMC 2758233. PMID 11520916.
Werner P, Paluru P, Simpson AM, Latney B, Iyer R, Brodeur GM, Goldmuntz E (December 2014). "Mutations in NTRK3 suggest a novel signaling pathway in human congenital heart disease". Human Mutation. 35 (12): 1459–68. doi:10.1002/humu.22688. PMC 4247247. PMID 25196463.
Jin W, Yun C, Kwak MK, Kim TA, Kim SJ (December 2007). "TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling". Oncogene. 26 (55): 7684–91. doi:10.1038/sj.onc.1210571. PMID 17546043. S2CID 44016529.
Shi L, Yue J, You Y, Yin B, Gong Y, Xu C, et al. (November 2006). "Dok5 is substrate of TrkB and TrkC receptors and involved in neurotrophin induced MAPK activation". Cellular Signalling. 18 (11): 1995–2003. doi:10.1016/j.cellsig.2006.03.007. PMID 16647839.
Jin W, Yun C, Kim HS, Kim SJ (October 2007). "TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling". Cancer Research. 67 (20): 9869–77. doi:10.1158/0008-5472.CAN-07-0436. PMID 17942918.
Marsh HN, Palfrey HC (September 1996). "Neurotrophin-3 and brain-derived neurotrophic factor activate multiple signal transduction events but are not survival factors for hippocampal pyramidal neurons". Journal of Neurochemistry. 67 (3): 952–63. doi:10.1046/j.1471-4159.1996.67030952.x. PMID 8752100.
Yuen EC, Mobley WC (September 1999). "Early BDNF, NT-3, and NT-4 signaling events". Experimental Neurology. 159 (1): 297–308. doi:10.1006/exnr.1999.7148. PMID 10486198. S2CID 31007329.
Zaccaro MC, Lee HB, Pattarawarapan M, Xia Z, Caron A, L'Heureux PJ, et al. (September 2005). "Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities". Chemistry & Biology. 12 (9): 1015–28. doi:10.1016/j.chembiol.2005.06.015. PMID 16183026.
Brahimi F, Malakhov A, Lee HB, Pattarawarapan M, Ivanisevic L, Burgess K, Saragovi HU (October 2009). "A peptidomimetic of NT-3 acts as a TrkC antagonist". Peptides. 30 (10): 1833–9. doi:10.1016/j.peptides.2009.07.015. PMC 2755609. PMID 19647025.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Takahashi H, Arstikaitis P, Prasad T, Bartlett TE, Wang YT, Murphy TH, Craig AM (January 2011). "Postsynaptic TrkC and presynaptic PTPσ function as a bidirectional excitatory synaptic organizing complex". Neuron. 69 (2): 287–303. doi:10.1016/j.neuron.2010.12.024. PMC 3056349. PMID 21262467.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. (February 2018). "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children". The New England Journal of Medicine. 378 (8): 731–739. doi:10.1056/NEJMoa1714448. PMC 5857389. PMID 29466156.
Bouzas-Rodriguez J, Cabrera JR, Delloye-Bourgeois C, Ichim G, Delcros JG, Raquin MA, et al. (March 2010). "Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis". The Journal of Clinical Investigation. 120 (3): 850–8. doi:10.1172/jci41013. PMC 2827960. PMID 20160348.
Jin W (January 2020). "Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer". Cancers. 12 (1): 147. doi:10.3390/cancers12010147. PMC 7016819. PMID 31936239..
Saragovi HU, Galan A, Levin LA (31 January 2019). "Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration". Frontiers in Cellular Neuroscience. 13 (231): 231. doi:10.3389/fncel.2019.00231. PMC 6563757. PMID 31244606.
Kue CS, Kamkaew A, Voon SH, Kiew LV, Chung LY, Burgess K, Lee HB (November 2016). "Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy". Scientific Reports. 6 (37209): 37209. Bibcode:2016NatSR...637209K. doi:10.1038/srep37209. PMC 5112560. PMID 27853305.
Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, et al. (October 2015). "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101". Cancer Discovery. 5 (10): 1049–57. doi:10.1158/2159-8290.CD-15-0443. PMC 4635026. PMID 26216294.
Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, et al. (May 2009). "Trk receptor expression and inhibition in neuroblastomas". Clinical Cancer Research. 15 (10): 3244–50. doi:10.1158/1078-0432.ccr-08-1815. PMC 4238907. PMID 19417027.
Luo Y, Kaz AM, Kanngurn S, Welsch P, Morris SM, Wang J, et al. (2013-07-11). "NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer". PLOS Genetics. 9 (7): e1003552. doi:10.1371/journal.pgen.1003552. PMC 3708790. PMID 23874207.
Behrouz Sharif S, Hashemzadeh S, Mousavi Ardehaie R, Eftekharsadat A, Ghojazadeh M, Mehrtash AH, et al. (December 2016). "Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker". Oncology Letters. 12 (6): 5335–5343. doi:10.3892/ol.2016.5327. PMC 5228494. PMID 28105243.
Kuo IY, Chang JM, Jiang SS, Chen CH, Chang IS, Sheu BS, et al. (2014). "Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients". International Journal of Medical Sciences. 11 (8): 779–87. doi:10.7150/ijms.7405. PMC 4057483. PMID 24936140.
Coles CH, Mitakidis N, Zhang P, Elegheert J, Lu W, Stoker AW, et al. (November 2014). "Structural basis for extracellular cis and trans RPTPσ signal competition in synaptogenesis". Nature Communications. 5 (5209): 5209. Bibcode:2014NatCo...5.5209C. doi:10.1038/ncomms6209. PMC 4239663. PMID 25385546.
Huang EJ, Reichardt LF (March 2001). "Neurotrophins: roles in neuronal development and function". Annual Review of Neuroscience. 24: 677–736. doi:10.1146/annurev.neuro.24.1.677. PMC 2758233. PMID 11520916.
Werner P, Paluru P, Simpson AM, Latney B, Iyer R, Brodeur GM, Goldmuntz E (December 2014). "Mutations in NTRK3 suggest a novel signaling pathway in human congenital heart disease". Human Mutation. 35 (12): 1459–68. doi:10.1002/humu.22688. PMC 4247247. PMID 25196463.
Brahimi F, Malakhov A, Lee HB, Pattarawarapan M, Ivanisevic L, Burgess K, Saragovi HU (October 2009). "A peptidomimetic of NT-3 acts as a TrkC antagonist". Peptides. 30 (10): 1833–9. doi:10.1016/j.peptides.2009.07.015. PMC 2755609. PMID 19647025.

reactome.org

Tsoulfas, P. (2018). "Signaling by NTRK3 (TRKC)". Reactome - A Curated Knowledgebase of Biological Pathways. 65. doi:10.3180/R-HSA-9034015.1. S2CID 89660152.

sciencedirect.com

Benito-Gutiérrez E, Garcia-Fernàndez J, Comella JX (February 2006). "Origin and evolution of the Trk family of neurotrophic receptors". Molecular and Cellular Neurosciences. 31 (2): 179–92. doi:10.1016/j.mcn.2005.09.007. PMID 16253518. S2CID 25232377.

semanticscholar.org

api.semanticscholar.org

Tsoulfas, P. (2018). "Signaling by NTRK3 (TRKC)". Reactome - A Curated Knowledgebase of Biological Pathways. 65. doi:10.3180/R-HSA-9034015.1. S2CID 89660152.
Naito Y, Lee AK, Takahashi H (March 2017). "Emerging roles of the neurotrophin receptor TrkC in synapse organization". Neuroscience Research. 116 (2017): 10–17. doi:10.1016/j.neures.2016.09.009. PMID 27697534. S2CID 44805812.
Benito-Gutiérrez E, Garcia-Fernàndez J, Comella JX (February 2006). "Origin and evolution of the Trk family of neurotrophic receptors". Molecular and Cellular Neurosciences. 31 (2): 179–92. doi:10.1016/j.mcn.2005.09.007. PMID 16253518. S2CID 25232377.
Barbacid M (April 1995). "Neurotrophic factors and their receptors". Current Opinion in Cell Biology. 7 (2): 148–55. doi:10.1016/0955-0674(95)80022-0. PMID 7612265. S2CID 12525700.
Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M (December 1982). "Oncogenes in solid human tumours". Nature. 300 (5892): 539–42. Bibcode:1982Natur.300..539P. doi:10.1038/300539a0. PMID 7144906. S2CID 30179526.
Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, et al. (November 2020). "Evaluating entrectinib as a treatment option for non-small cell lung cancer". Expert Opinion on Pharmacotherapy. 21 (16): 1935–1942. doi:10.1080/14656566.2020.1798932. PMID 32736487. S2CID 220907958.
Marcus L, Donoghue M, Aungst S, Myers CE, Helms WS, Shen G, et al. (February 2021). "FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors". Clinical Cancer Research. 27 (4): 928–932. doi:10.1158/1078-0432.CCR-20-2771. PMID 32967940. S2CID 221886243.
Lamballe, L; Klein, R; Barbecid, M (6 September 1991). "TrkC, a new member of the TrkC family of tyrosine protein kinases, is a receptor for Neurotrophin-3". Cell. 66 (5): 967–979. doi:10.1016/0092-8674(91)90442-2. PMID 1653651. S2CID 23448391.
Jin W, Yun C, Kwak MK, Kim TA, Kim SJ (December 2007). "TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling". Oncogene. 26 (55): 7684–91. doi:10.1038/sj.onc.1210571. PMID 17546043. S2CID 44016529.
Yuen EC, Mobley WC (September 1999). "Early BDNF, NT-3, and NT-4 signaling events". Experimental Neurology. 159 (1): 297–308. doi:10.1006/exnr.1999.7148. PMID 10486198. S2CID 31007329.